328P - Correlation between body mass index, diabetes and outcome in a cohort of Egyptian early breast cancer patients

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Cancer in Special Situations
Breast Cancer
Presenter Noha Ahmed
Citation Annals of Oncology (2014) 25 (suppl_4): iv85-iv109. 10.1093/annonc/mdu327
Authors N.A. Ahmed, M.A. Ismail, O. Abdel-Rahman, R. Malek
  • Oncology, Kasr alainy Hospital, 5575 - Cairo/EG



Diabetes and cancer are two commonly coexisting conditions with many epidemiological studies suggesting potentially causal association between type 2 diabetes and three of the five leading causes of cancer mortality (carcinoma of the colon, breast and pancreas). A potential explanation lays in the fact that obesity and hyperglycemia may lead to increased oxidative stress which may contribute to increase cancer risk in diabetic patients. Our current analysis aims to investigate whether Adjuvant breast cancer women with diabetes and BMI (body mass index) >30 have statistically increased risk for relapse.


Breast cancer patients treated at a clinical oncology department in a governmental hospital, (Cairo, Egypt) in the period 2005-2010 were reviewed. The study population consisted of patients with early breast cancer patients. We investigated the correlation between diabetes, obesity and both DFS (disease free survival) and OS (overall survival) in this cohort of patients.


A total of 431 early breast cancer patients were included fulfilling inclusion criteria. Median age was 54 years old. The patients were divided in 2 groups based on body mass index calculation: 154 Non obese with BMI <30, and 182 obese with BMI>30 while BMI calculation was not applicable for the rest of the group (95 patients). For both DFS and OS analyses, we found no significant differences between the 2 groups (obese vs. non obese) (P value =0.089 and P = 0.0657 respectively). When classifying the same group of patient according to diabetic status, 82 patients were found to have diabetes Mellitus while 349 patients were non diabetics; the P value for DFS was also non significant (p= 0.635). When further analyzing the diabetic group according to BMI, patients with diabetes and BMI higher than 30 were found to have a significantly shorter DFS and higher risk of relapse (P =0.041).


According to our data, diabetic breast cancer patients with higher BMI have a higher risk of relapse compared to other subsets of patients. Further research into the underlying molecular pathogenetic events as well as personalized targeted therapies is highly recommended for this high risk cohort of patients.


All authors have declared no conflicts of interest.